SCHEMBL20595207

SCHEMBL20595207

COc1cc(C(F)(F)F)ccc1OCCNC(=O)c1cc(C)nc(NC(=O)C(C)C)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.65
ALOX5 P09917 2/20 0.44
EPHX2 P34913 2/20 0.44
MCHR1 Q99705 2/20 0.43
MAPT P10636 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.42
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
ALDH1A1 P00352 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
KMT2A Q03164 3/20 0.41
HTT P42858 2/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
HSP90AA1 P07900 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PPARD Q03181 1/20 0.40
PPARA Q07869 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30450908 1.00 SCN9A (0.65) SCN9AALOX5EPHX2MCHR1MAPT
SCHEMBL22797803 0.92 SCN9A (0.68) SCN9AMAPTRAB9AKDM4EHPGD
SCHEMBL30449593 0.92 SCN9A (0.68) SCN9AMAPTRAB9AKDM4EHPGD
SCHEMBL22798285 0.90 SCN9A (0.66) SCN9AMAPTRAB9AKDM4EHPGD
SCHEMBL20595186 0.90 SCN9A (0.52) SCN9AALOX5EPHX2MCHR1MAPT
SCHEMBL22797766 0.90 SCN9A (0.73) SCN9AMAPTKDM4EHPGDALDH1A1
SCHEMBL22797788 0.90 SCN9A (0.75) SCN9AMRGPRX4SMN1; SMN2
SCHEMBL22798228 0.89 SCN9A (0.51) SCN9AALOX5EPHX2MCHR1MAPT
SCHEMBL20595189 0.88 SCN9A (0.66) SCN9AMCHR1MAPTNPC1RAB9A
SCHEMBL30450528 0.88 SCN9A (0.66) SCN9AMCHR1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN claimed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US claimed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP claimed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN claimed
EP-3487839-A1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RaQualia Pharma Inc. (JP) 2019-05-29 EP claimed
WO-2018235851-A1 AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS RAQUALIA PHARMA INC. (JP) 2018-12-27 WO claimed
CN-110612285-B Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2023-04-04 CN disclosed
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers RAQUALIA PHARMA INC. (JP) 2021-10-26 US disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
EP-3487839-B1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RAQUALIA PHARMA INC (JP) 2020-12-23 EP disclosed
CN-110612285-A Amide derivatives as Nav1.7 and Nav1.8 blockers 拉夸里亚创药株式会社 2019-12-24 CN disclosed
EP-3487839-A1 AMIDE DERIVATIVES AS NAV1.7 AND NAV1.8 BLOCKERS RaQualia Pharma Inc. (JP) 2019-05-29 EP disclosed
WO-2018235851-A1 AMIDE DERIVATIVES AS Nav1.7 and Nav1.8 BLOCKERS RAQUALIA PHARMA INC. (JP) 2018-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11154544-B2 Amide derivatives as Nav1.7 and Nav1.8 blockers SCN8A, SCN7A, SCN1A SCN9A 9/4885ALOX5 2959/4885EPHX2 3915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.